Novartis wants to amend invalidated patent for MS drug
Intellectual Property July 2, 2019 1:30 pm By Amelia Birnie | Sydney

Novartis has applied to amend its proposed patent for an oral form of multiple sclerosis drug Gilenya, as it appeals an invalidity ruling by IP […]

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Want to test drive Lawyerly? Contact us to take a free trial.